{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T08:18:50Z","timestamp":1782548330862,"version":"3.54.5"},"reference-count":28,"publisher":"American Society for Microbiology","issue":"3","license":[{"start":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T00:00:00Z","timestamp":1741132800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T00:00:00Z","timestamp":1741132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2025,3,5]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:sec>\n            <jats:title\/>\n            <jats:p>Coronavirus disease 2019, which leads to pneumonia, is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). RAY1216 is a 3C-like protease inhibitor that targets SARS-CoV-2. The aim of our study was to assess the pharmacokinetics (PK) and safety of RAY1216 in healthy volunteers. This was a randomized, placebo-controlled, double-blind study consisting of four components: a single ascending dose study, a drug-drug interaction study, a multiple ascending dose study, and a food-effect study. All participants were randomly assigned to receive either a single dose or multiple doses of RAY1216 or placebo. A total of 88 healthy adult participants (male-to-female ratio of 1:1) aged 18\u201350 years were enrolled. A total of 37 participants (42%) experienced at least one adverse event (AE). All AEs were mild or moderate and were resolved without additional treatment. The most commonly reported adverse drug reactions were hypertriglyceridemia, hyperuricemia, and elevated serum creatinine levels. RAY1216 was well-absorbed after administration with exposure increasing in a dose-dependent manner. Food appeared to increase exposure and delay the absorption of RAY1216. Ritonavir significantly inhibited drug metabolism, and increased drug exposure increased the associated safety risks. RAY1216 was found to be well tolerated and safe in healthy participants. On the basis of preclinical results, PK characteristics, and the safety profile of RAY1216, a dosage of 400 mg three times daily was selected, thereby establishing a foundation for future research and for the clinical application of RAY1216.<\/jats:p>\n            <jats:sec>\n              <jats:title>CLINICAL TRIALS<\/jats:title>\n              <jats:p>\n                This study is registered with ClinicalTrials.gov as\n                <jats:related-object xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" document-id=\"NCT05829551\" document-id-type=\"clinical-trial-number\" source-id=\"ClinicalTrials.gov\" source-id-type=\"registry-name\" source-type=\"clinical-trials-registry\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT05829551\">NCT05829551<\/jats:related-object>\n                .\n              <\/jats:p>\n            <\/jats:sec>\n          <\/jats:sec>","DOI":"10.1128\/aac.01450-24","type":"journal-article","created":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T14:03:52Z","timestamp":1738332232000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":5,"title":["Single- and multiple-dose pharmacokinetics and safety of the SARS-CoV-2 3CL protease inhibitor RAY1216: a phase 1 study in healthy participants"],"prefix":"10.1128","volume":"69","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8281-761X","authenticated-orcid":true,"given":"Yue","family":"Hu","sequence":"first","affiliation":[{"name":"Phase I Clinical Research Center, First Hospital of Jilin University","place":["Changchun, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haijun","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Anatomy and Neurobiology, School of Basic Medical Science, Central South University","place":["Changsha, China"]},{"name":"Guangdong Raynovent Biotech Co., Ltd.","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Wang","sequence":"additional","affiliation":[{"name":"Shanghai Qiangshi Information Technology Co., Ltd.","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dandan","family":"Wu","sequence":"additional","affiliation":[{"name":"Phase I Clinical Research Center, First Hospital of Jilin University","place":["Changchun, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Phase I Clinical Research Center, First Hospital of Jilin University","place":["Changchun, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2320-4404","authenticated-orcid":true,"given":"Yanhua","family":"Ding","sequence":"additional","affiliation":[{"name":"Phase I Clinical Research Center, First Hospital of Jilin University","place":["Changchun, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junyan","family":"Wu","sequence":"additional","affiliation":[{"name":"Phase I Clinical Trial Centre, Sun Yat-sen Memorial Hospital, Sun Yat-sen University","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suiwen","family":"Ye","sequence":"additional","affiliation":[{"name":"Phase I Clinical Trial Centre, Sun Yat-sen Memorial Hospital, Sun Yat-sen University","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Peng","sequence":"additional","affiliation":[{"name":"Guangdong Raynovent Biotech Co., Ltd.","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5904-3692","authenticated-orcid":true,"given":"Li","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, First Hospital of Jilin University","place":["Changchun, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30185-9"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2020.01.009"},{"key":"e_1_3_4_4_2","unstructured":"WHO. 2019. Coronavirus (COVID-19) dashboard. Available from: https:\/\/www. who.int\/emergencies\/diseases\/novel-coronavirus-2019. Retrieved 08 Jan 2025."},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2023184"},{"key":"e_1_3_4_6_2","unstructured":"WHO. 2023. Drugs to prevent COVID-19: living guideline. Available from: https:\/\/www.who.int\/publications\/i\/item\/WHO-2019-nCoV-prophylaxes-2023.1. Retrieved 07 Jan 2025."},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40267-022-00897-8"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2021.100794"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-022-01692-5"},{"key":"e_1_3_4_10_2","unstructured":"EMA. 2022. COVID-19: EMA recommends conditional marketing authorisation for Paxlovid. Available from: https:\/\/www.ema.europa.eu\/en\/news\/covid-19-ema-recommends- conditional-marketing-authorisation-paxlovid. Retrieved 07 Jan 2025."},{"key":"e_1_3_4_11_2","unstructured":"Australian Government Therapeutic Goods Administration. 2022. TGA provisionally approves two oral COVID-19 treatments molnupiravir (LAGEVRIO) and nirmatrelvir + ritonavir (PAXLOVID). Available from: https:\/\/www.tga.gov.au\/. Retrieved 08 Jan 2025."},{"key":"e_1_3_4_12_2","unstructured":"Govemment of Canada. 2022. Health Canada authorizes PAXLOVIDTM for patients with mild to moderate COVID-19 at high risk of developing serious disease. Available from: https:\/\/www.canada.ca. Retrieved 07 Jan 2025."},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2223-y"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12668"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23179866"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkh029"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-014-0167-9"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2603"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41564-024-01618-9"},{"key":"e_1_3_4_20_2","unstructured":"WHO. 2024. Tracking SARS-CoV-2 variants. Available from: https:\/\/www.who. int\/en\/activities\/tracking-SARS-CoV-2-variants\/. Retrieved 07 Jan 2025."},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmgm.2021.108042"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2022.128629"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10928-017-9558-5"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1449583"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(21)00633-2"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.abl4784"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2118542"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.3238\/arztebl.m2022.0152"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00632-22"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.01450-24","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.01450-24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T05:12:48Z","timestamp":1743743568000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/aac.01450-24"}},"subtitle":[],"editor":[{"given":"Miguel Angel","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,3,5]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3,5]]}},"alternative-id":["10.1128\/aac.01450-24"],"URL":"https:\/\/doi.org\/10.1128\/aac.01450-24","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,5]]},"assertion":[{"value":"2024-09-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-15","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-31","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e01450-24"}}